Clinical PET of neuroendocrine tumors using 64Cu-DOTATATE: first-in-humans study

Andreas Klaus Pfeifer, Ulrich Knigge, Jann Mortensen, Peter Oturai, Anne Kiil Berthelsen, Annika Loft, Tina Binderup, Palle Rasmussen, Dennis Ringkjøbing Elema, Thomas Levin Klausen, Søren Holm, Eric von Benzon, Liselotte Højgaard, Andreas Kjaer

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

160 Citationer (Scopus)

Abstract

The use of positron emitter-labeled compounds for somatostatin receptor imaging (SRI) has become attractive because of the prospect of improved spatial resolution, accelerated imaging procedures, and the ability to quantify tissue radioactivity concentrations. This paper provides results from first-in-humans use of (64)Cu-DOTATATE, an avidly binding somatostatin receptor ligand linked to a radioisotope with intermediate half-life and favorable positron energy (half-life, 12.7 h; maximum positron energy, 0.653 MeV).
OriginalsprogEngelsk
TidsskriftJournal of Nuclear Medicine
Vol/bind53
Udgave nummer8
Sider (fra-til)1207-15
Antal sider9
ISSN0161-5505
DOI
StatusUdgivet - aug. 2012

Citationsformater